新冠病毒试剂以及技术服务相关引用文献

到目前为止,新冠病毒引起的全球大流行仍未得到有效的控制,且目前没有针对新冠病毒的有效的预防或者治疗方式。科学研究者们仍在致力于诊断试剂、疫苗以及治疗性药物的开发。为了支持上述研究,义翘神州开发了一系列新冠病毒相关的蛋白、抗体等科研试剂。同时,基于先进的技术平台,义翘神州可快速高质的根据研究人员对试剂的需求进行相关试剂的定制服务。 为了更好地支持传染病领域的研究,义翘神州开发了病毒抗原试剂库,包括了近50种病毒、350种毒株的抗原蛋白试剂。

截止到6月15日,已有116篇正式发表或者预发表的学术文章中提及使用了义翘神州提供的新冠试剂或者技术服务。

1. Renhong Yan,et al.Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.Science.2020

2. Lamers, MM,et al.SARS-CoV-2 productively infects human gut enterocytes.Science.2020

3. Rockx, B,et al.Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.Science.2020

4. Yu, J,et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques.Science.2020

5. Xiangyang Chi,et al.A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.Science.2020

6. Bin Ju,et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection.Nature.2020

7. Linlin Bao,et al.The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice.Nature.2020

8. Dora Pinto,et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature.2020

9. Bojkova, D,et al.Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature.2020

10. "Yunlong Cao,et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.cell.2020"

11. Cao, Y,et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.Cell.2020

12. Wrapp, Daniel,et al.Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.Cell.2020

13. Sun, J,et al.Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.Cell.2020

14. Wang, H,et al.Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.Cell.2020

15. Wang, C,et al.A human monoclonal antibody blocking SARS-CoV-2 infection.Nature Communications .2020

16. Ou, X,et al.Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.Nature Communications .2020

17. Deng, W,et al.Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques.Nature Communications .2020

18. Smith, TRF,et al.Immunogenicity of a DNA vaccine candidate for COVID-19.Nature Communications .2020

19. Ni, L,et al.Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.Immunity.2020

20. Long, QX,et al.Antibody responses to SARS-CoV-2 in patients with COVID-19.Nature Medicine.2020

21. "Amanat F,et al.A serological assay to detect SARS-CoV-2 seroconversion in humans.Nature Medicine.2020"

22. Wu, Y,et al.Identification of Human Single-Domain Antibodies against SARS-CoV-2.Cell Host Microbe.2020

23. Zhang, H,et al.Activation of Peroxiredoxin 1 by Fluvastatin Effectively Protects from Inflammation and SARS-CoV-2.Cell Metabolism.2020

24. Huibin LvCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.Cell Reports.2020

25. Yi, C,et al.Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.Cell. Mol. Immunol..2020

26. Xiao, F,et al.Evidence for gastrointestinal infection of SARS-CoV-2.Gastroenterology.2020

27. Seo, G,et al.Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.ACS Nano.2020

28. Su, H,et al.Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.Kidney Int..2020

29. Ye, L,et al.Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.Cellular & Molecular Immunology.2020

30. Bing ZhaoRecapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids.Protein&Cell.2020

31. Chia, WN,et al.Serological differentiation between COVID-19 and SARS infections.Emerg Microbes Infect.2020

32. Sun B,et al.Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.Emerg Microbes Infect..2020

33. Shan-Meng Lin,et al.Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.J. Med. Chem..2020

34. Liu, X,et al.Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction.Acta Pharm Sin B.2020

35. Liu, X,et al.Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.Acta Pharm Sin B.2020

36. Okba, NMA,et al.Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.Emerging Infect. Dis..2020

37. Sangeun Jeon,et al.Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.Antimicrob Agents Chemother.2020

38. Zeng, W,et al.Biochemical characterization of SARS-CoV-2 nucleocapsid protein.Biochemical and Biophysical Research Communications.2020

39. Fujita, R,et al.Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system.Biochemical and Biophysical Research Communications.2020

40. Chen, Z,et al.A DNA Aptamer Based Method for Detection of SARS-CoV-2 Nucleocapsid Protein.Virol Sin.2020

41. Huang, S,et al.Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.Biomedical Journal.2020

42. Musarrat, F,et al.The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARSCoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.J Med Virol.2020

43. Pu, T,et al.Evaluate Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity by Pseudoviral Particles.J. Med. Virol..2020

44. Carnevale, S,et al.Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of CoViD-19 patient with diarrhea.J. Med. Virol..2020

45. Prasad, ASV;Local Immunity Concept in the Context of the Novel Corona Viral Infection: A Consideration.bioRxiv.2020

46. Zeng, X,et al.Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.Antibody Therapeutics.2020

47. Khan, S,et al.Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.BioRxiv.2020

48. Thornburg, N,et al.Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.bioRxiv.2020

49. Chunyun Sun,et al.SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development.bioRxiv.2020

50. Milewska, A,et al.HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV.bioRxiv.2020

51. Wang, C,et al.Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2.bioRxiv.2020

52. Li, Y,et al.Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1.bioRxiv.2020

53. Xiong, H,et al.Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells.bioRxiv.2020

54. Zhang, Q,et al.SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation.bioRxiv.2020

55. Zhang, Y,et al.Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry.bioRxiv.2020

56. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020

57. Tan, X,et al.Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples.bioRxiv.2020

58. Zhu, Y,et al.Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.bioRxiv.2020

59. Walter, JD,et al.Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain.BioRxiv.2020

60. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray.BioRxiv.2020

61. Chi X,et al.Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain.bioRxiv.2020

62. Kim, SY,et al.Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry.bioRxiv.2020

63. Si L,et al.Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics.bioRxiv.2020

64. Liu L,et al.SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner.bioRxiv.2020

65. Zha L,et al.Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles.bioRxiv.2020

66. Romano, M,et al.An engineered stable mini-protein to plug SARS-Cov2 Spikes.bioRxiv.2020

67. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020

68. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray.BioRxiv.2020

69. Hedde, PN,et al.A Modular Microarray Imaging System for Highly Specific COVID-19 Antibody Testing.bioRxiv.2020

70. Ghazizadeh, Z,et al.Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men.bioRxiv.2020

71. Finch, CL,et al.Characteristic and quantifiable COVID-19-like abnormalities in CT-and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis).bioRxiv.2020

72. Cai, Y,et al.Distinct conformational states of SARS-CoV-2 spike protein.bioRxiv.2020

73. Zang, J,et al.Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.bioRxiv.2020

74. Zost, SJ,et al.Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.bioRxiv.2020

75. Zhang, Y,et al.The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I.bioRxiv.2020

76. Corbett, K,et al.SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.bioRxiv.2020

77. Yang, Y,et al.The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.bioRxiv.2020

78. Daly, J,et al.Neuropilin-1 is a host factor for SARS-CoV-2 infection.bioRxiv.2020

79. Liu, D,et al.Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection.bioRxiv.2020

80. Mesci, P,et al.Sofosbuvir protects human brain organoids against SARS-CoV-2.bioRxiv.2020

81. Bosco-Lauth, A,et al.Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats.bioRxiv.2020

82. Yao, D,et al.Human H-ferritin presenting RBM of spike glycoprotein as potential vaccine of SARS-CoV-2.bioRxiv.2020

83. Liu, L,et al.A translatable subunit nanovaccine for COVID-19.ChemRxiv.2020

84. Song, Y,et al.Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.ChemRxiv.2020

85. Sobrevilla, JMV;¿ Por qué los pacientes con diabetes o hipertensión son más susceptibles a tener COVID-19?.Conference.2020

86. Harcourt, Jennifer,et al.Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States.Emerging Infectious Diseases.2020

87. Feng, Siqin,et al.Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases.2020

88. Zeng, X,et al.Molecular Detection of SARS-CoV-2 in Formalin Fixed Paraffin Embedded Specimens.JCI Insight.2020

89. Larsen, CP,et al.Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19).Kidney Int Rep.2020

90. Jiang, H,et al.Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray.medRxiv.2020

91. Bo Diao,et al.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv.2020

92. Linlin Bao,et al.Reinfection could not occur in SARS-CoV-2 infected rhesus macaques.medRxiv.2020

93. Linlin Bao,et al.Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route.medRxiv.2020

94. Ke Wang,et al.SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.medRxiv.2020

95. Feng, Z,et al.The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes.medRxiv.2020

96. Wei, C,et al.Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies.medRxiv.2020

97. McAndrews, KM,et al.Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19.medRxiv.2020

98. Norman, M,et al.Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients.medRxiv.2020

99. Randad, PR,et al.COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva.medRxiv.2020

100. Rosenberg, ES,et al.Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York.medRxiv.2020

101. Phipps, WS,et al.SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity.medRxiv.2020

102. Chakraborty, S,et al.Symptomatic SARS-CoV-2 infections display specific IgG Fc structures.medRxiv.2020

103. Rosendal, E,et al.Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA..medRxiv.2020

104. Mittal, A,et al.COVID-19 Pandemic: Insights into Structure, Function, and hACE2 Receptor Recognition by the SARS-CoV-2.preprints.2020

105. Simon, D,et al.Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection.Research Square.2020

106. Kanjanasirirat, P,et al.High-Content Screening of Thai Medicinal Plants Reveals Boesenbergia rotunda Extract and its Component Panduratin A as Anti-SARS-CoV-2 Agents.Research Square.2020

107. Yang, J,et al.Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.Research Square.2020

108. Bdr-Eldeen, O;What we should understand about SARS-COV-2 GENOME..researchgate.net.2020

109. Ravichandran, Supriya,et al.Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.Science Translational Medicine.2020

110. Zhou, R,et al.Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.SSRN Journal.2020

111. Cheng, Y,et al.Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.SSRN Journal.2020

112. 彭浩然,et al.上海 2 株严重急性呼吸综合征冠状病毒 2 的分离与鉴定.第二军医大学学报.2020

113. Yu, P,et al.Age-related rhesus macaque models of COVID-19.Anim Models Exp Med.2020

114. Turista, D,et al.Distribution of COVID-19 and Phylogenetic Tree Construction of SARS-CoV-2 in Indonesia.J. Pure Appl. Microbiol..2020

115. Belete, T;A review on Promising vaccine development progress for COVID-19 disease.Vacunas.2020

116. Gan, JH;Discovery of small molecule therapeutics for the Middle Eastern respiratory syndrome-coronavirus (MERS-CoV).Thesis.2020

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8

如下列举了部分在发表文献中引用的产品详情。

Cat# Molecule Description Total Cites Citation Number
40591-V08H Spike S1 SARS-CoV-2 Spike S1,His tag, HPLC-verified 20 7,17,18,22,27,29,32,47,49,51,55,57,60,68,92,93,96,98,109,113
40589-V08B1 Spike S1+S2 ECD SARS-CoV-2 Spike S1+S2 ECD,His tag 13 11,18,47,55,59,60,61,64,68,84,96,99,109
40592-V05H Spike RBD SARS-CoV-2 Spike RBD,mFc tag, HPLC-verified 13 1,8,12,29,47,53,59,60,61,68,73,74,84
40588-V08B NP-CoV SARS-CoV-2 Nucleocapsid,His tag 6 32,47,60,68,99,101
40590-V08B Spike S2 SARS-CoV-2 Spike S2,His tag 6 24,47,58,60,68,109
40592-V08B Spike RBD SARS-CoV-2 Spike RBD,His tag 6 11,22,29,46,61,84
40591-V02H Spike S1 SARS-CoV-2 Spike S1,Fc tag 5 47,56,60,67,68
40592-V08H Spike RBD SARS-CoV-2 Spike RBD,His tag 4 66,97,99,109
40591-V05H1 Spike S1 SARS-CoV-2 Spike S1,mFc Tag 3 47,60,68
40592-V02H Spike RBD SARS-CoV-2 Spike RBD,Fc tag 1 70
40592-V08B-B Spike RBD SARS-CoV-2 Spike RBD,His tag 1 11
40592-V31H Spike RBD SARS-CoV-2 Spike RBD,rFc Tag 1 8
40150-V08B1 Spike S1 SARS-CoV Spike S1,His tag 9 8,18,20,47,49,58,60,61,68
40143-V08B NP-CoV SARS-CoV Nucleocapsid,His tag 5 20,36,47,60,68
40150-V08B2 Spike RBD SARS-CoV Spike RBD,His tag 4 47,58,60,68
40150-V31B2 Spike RBD SARS-CoV Spike RBD,rFc Tag 4 47,49,60,68
40524-V08E PLpro SARS-CoV PLpro,His tag 3 47,60,68
40069-V08H Spike S1 MERS-CoV Spike S1,His tag 5 27,47,49,60,68
40068-V08B NP-CoV MERS-CoV Nucleocapsid,His tag 3 47,60,68
40069-V08B Spike S1+S2 ECD MERS-CoV Spike S1+S2 ECD,His tag 3 47,60,68
40069-V08B1 Spike S1 MERS-CoV Spike S1,His tag 3 47,60,68
40070-V08B Spike S2 MERS-CoV Spike S2,His tag 3 47,60,68
40071-V05B Spike RBD MERS-CoV Spike RBD,mFc Tag 3 47,60,68
40071-V08B1 Spike RBD MERS-CoV Spike RBD,His tag 3 47,60,68
40071-V31B Spike RBD MERS-CoV Spike RBD,rFc Tag 3 47,60,68
40071-V31B1 Spike RBD MERS-CoV Spike RBD,rFc Tag 3 47,60,68
40603-V08H HE-CoV HCoV-OC43 HE-CoV,His tag 3 47,60,68
40607-V08B Spike S1+S2 ECD HCoV-OC43 Spike S1+S2 ECD,His tag 3 47,60,68
40600-V08H Spike S1 HCoV-NL63 Spike S1,His tag 4 21,47,60,68
40604-V08B Spike S1+S2 ECD HCoV-NL63 Spike S1+S2 ECD,His tag 3 47,60,68
40021-V08H Spike S1 HCoV-HKU1 Spike S1,His tag 3 47,60,68
40602-V08H Spike S1 HCoV-HKU1 Spike S1,His tag 3 47,60,68
40606-V08B Spike S1+S2 ECD HCoV-HKU1 Spike S1+S2 ECD,His tag 3 47,60,68
40601-V08H Spike S1 HCoV-229E Spike S1,His tag 4 21,47,60,68
40605-V08B Spike S1+S2 ECD HCoV-229E Spike S1+S2 ECD,His tag 4 47,60,68,99
11049-V08B RSV-F RSV RSV-F,His tag 3 47,60,68
11070-V08H RSV-G RSV RSV-G,His tag 3 47,60,68
13029-V08H RSV-G RSV RSV-G,His tag 3 47,60,68
40037-V08B RSV-F RSV RSV-F,His tag 3 47,60,68
11716-V08H HA1 Influenza B HA1,His tag 3 47,60,68
11716-V08H1 HA1 Influenza B HA1,His tag 3 47,60,68
40498-V08B HA Influenza B HA,His tag 3 47,60,68
40498-V08H1 HA Influenza B HA,His tag 3 47,60,68
10108-H08H ACE2 Human ACE2,His tag, HPLC-verified 3 29,61,84
10108-H02H ACE2 Human ACE2,Fc tag 1 51
10108-H05H ACE2 Human ACE2,Fc tag 1 46
10108-H08B ACE2 Human ACE2,His tag, HPLC-verified 1 11
10602-HNAE TNF Human TNF,native 1 22
40103-V08H HA1 H7N9 HA1,His tag 3 47,60,68
40103-V08H1 HA1 H7N9 HA1,His tag 3 47,60,68
10003-V06H1 HA1 H5N1 HA1,His & Fc Tag 3 47,60,68
10003-V06H3 HA1 H5N1 HA1,His & Fc Tag 3 47,60,68
40354-V08B HA1 H3N2 HA1,His tag 3 47,60,68
40354-V08H1 HA1 H3N2 HA1,His tag 3 47,60,68
40035-V08H HA1 H1N1 HA1,His tag 3 47,60,68
40035-V08H1 HA1 H1N1 HA1,His tag 3 47,60,68
40458-V08B DcCoV-NP DcCoV Nucleocapsid,His tag 3 47,60,68
Cat# Description Antigen Type Total Cites Citation Number
40143-T62 SARS-CoV Nucleocapsid Antibody NP-CoV Rabbit PAb 4 3,26,28,35
40150-T52 SARS-CoV Spike Antibody Spike Rabbit PAb 4 43,48,49,86
40143-R019 SARS-CoV-2 Nucleocapsid Antibody NP-CoV Rabbit MAb 3 9,89,95
40150-R007 SARS-CoV-2 Spike Antibody Spike Rabbit MAb 3 27,51,94
40150-T62 SARS-CoV Spike S1 Antibody Spike S1 Rabbit PAb 3 16,88,104
40592-T62 SARS-CoV-2 Spike RBD Antibody Spike RBD Rabbit PAb 3 47,60,68
10108-RP01 Human ACE2 Antibody ACE2 Rabbit PAb 2 30,95
40143-R001 SARS-CoV Nucleocapsid Antibody NP-CoV Rabbit MAb 2 37,91
10108-T56 Human ACE2 Antibody ACE2 Rabbit PAb 1 26
11695-RP01 HIV Gag-p24 Antibody Gag-p24 Rabbit PAb 1 16
11973-MM05T-H M13 Antibody M13 Mouse MAb 1 46
40068-MM10 MERS-CoV Nucleocapsid Antibody NP-CoV Mouse MAb 1 50
40068-RP02 MERS-CoV Nucleocapsid Antibody NP-CoV Rabbit PAb 1 33
40070-MM11 MERS-CoV Spike s2 Antibody Spike s2 Mouse MAb 1 16
40150-D001 SARS-CoV Spike Antibody Spike Chimeric MAb 1 63
40150-MM02 SARS-CoV Spike S1 Antibody Spike S1 Mouse MAb 1 16
40150-RP01 SARS-CoV Spike S1 Antibody Spike S1 Rabbit PAb 1 49
HG1K Human IgG1, kappa Isotype Control   kappa Isotype Control 1 11
SSA009 Goat Anti-Human IgG Secondary Antibody (Biotin)   Secondary Antibody 1 19
Novel Immunodiagnostics for COVID-19